Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia
- PMID: 29864118
- PMCID: PMC5986145
- DOI: 10.1371/journal.pone.0197737
Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia
Abstract
Background: Multidrug drug-resistant tuberculosis (MDR-TB) is a major health problem and seriously threatens TB control and prevention efforts globally. Ethiopia is among the 30th highest TB burden countries for MDR-TB with 14% prevalence among previously treated cases. The focus of this study was on determining drug resistance patterns of Mycobacterium tuberculosis among MDR-TB suspected cases and associated risk factors.
Methods: A cross-sectional study was conducted in Addis Ababa from June 2015 to December 2016. Sputum samples and socio-demographic data were collected from 358 MDR-TB suspected cases. Samples were analyzed using Ziehl-Neelsen technique, GeneXpert MTB/RIF assay, and culture using Lowenstein-Jensen and Mycobacterial growth indicator tube. Data were analyzed using SPSS version 23.
Results: A total of 226 the study participants were culture positive for Mycobacterium tuberculosis, among them, 133 (58.8%) participants were males. Moreover, 162 (71.7%) had been previously treated for tuberculosis, while 128 (56.6%) were TB/HIV co-infected. A majority [122 (54%)] of the isolates were resistant to any first-line anti-TB drugs. Among the resistant isolates, 110 (48.7%) were determined to be resistant to isoniazid, 94 (41.6%) to streptomycin, 89 (39.4%) to rifampicin, 72 (31.9%) to ethambutol, and 70 (30.9%) to pyrazinamide. The prevalence of MDR-TB was 89 (39.4%), of which 52/89 (58.4%) isolates were resistance to all five first-line drugs. Risk factors such as TB/HIV co-infection (AOR = 5.59, p = 0.00), cigarette smoking (AOR = 3.52, p = 0.045), alcohol drinking (AOR = 5.14, p = 0.001) hospital admission (AOR = 3.49, p = 0.005) and visiting (AOR = 3.34, p = 0.044) were significantly associated with MDR-TB.
Conclusions: The prevalence of MDR-TB in the study population was of a significantly high level among previously treated patients and age group of 25-34. TB/HIV coinfection, smoking of cigarette, alcohol drinking, hospital admission and health facility visiting were identified as risk factors for developing MDR-TB. Therefore, effective strategies should be designed considering the identified risk factors for control of MDR-TB.
Conflict of interest statement
All authors declare that they have no conflict of interest associated with the publication of this manuscript.
Figures
Similar articles
-
Primary and secondary anti-tuberculosis drug resistance in Hitossa District of Arsi Zone, Oromia Regional State, Central Ethiopia.BMC Public Health. 2016 Jul 18;16:593. doi: 10.1186/s12889-016-3210-y. BMC Public Health. 2016. PMID: 27430266 Free PMC article.
-
Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia: A cross-sectional study.PLoS One. 2020 Aug 14;15(8):e0236362. doi: 10.1371/journal.pone.0236362. eCollection 2020. PLoS One. 2020. PMID: 32797053 Free PMC article.
-
Relatively low primary drug resistant tuberculosis in southwestern Ethiopia.BMC Res Notes. 2012 May 10;5:225. doi: 10.1186/1756-0500-5-225. BMC Res Notes. 2012. PMID: 22574696 Free PMC article.
-
Drug-resistant tuberculosis in Ethiopia: problem scenarios and recommendation.Ethiop Med J. 2002 Jan;40(1):79-86. Ethiop Med J. 2002. PMID: 12240570 Review.
-
Anti-tuberculosis drug resistance in Ethiopia: systematic review.Int J Tuberc Lung Dis. 2017 Jan 1;21(1):18-22. doi: 10.5588/ijtld.16.0286. Int J Tuberc Lung Dis. 2017. PMID: 28157460
Cited by
-
Detection of Mycobacterium tuberculosis using Gene Xpert-MTB/RIF assay among tuberculosis suspected patients at Mizan-Tepi university teaching hospital, southwest Ethiopia: An institution based cross-sectional study.PLoS One. 2022 Nov 23;17(11):e0277536. doi: 10.1371/journal.pone.0277536. eCollection 2022. PLoS One. 2022. PMID: 36417400 Free PMC article.
-
Molecular detection of multidrug resistance pattern and associated gene mutations in M. tuberculosis isolates from newly diagnosed pulmonary tuberculosis patients in Addis Ababa, Ethiopia.PLoS One. 2020 Aug 4;15(8):e0236054. doi: 10.1371/journal.pone.0236054. eCollection 2020. PLoS One. 2020. PMID: 32750053 Free PMC article.
-
The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia.PLoS One. 2020 Feb 13;15(2):e0229040. doi: 10.1371/journal.pone.0229040. eCollection 2020. PLoS One. 2020. PMID: 32053661 Free PMC article.
-
Characteristics of TB/HIV Co-Infection and Patterns of Multidrug-Resistance Tuberculosis in the Northwest Amhara, Ethiopia.Infect Drug Resist. 2023 Jun 16;16:3829-3845. doi: 10.2147/IDR.S412951. eCollection 2023. Infect Drug Resist. 2023. PMID: 37346368 Free PMC article.
-
Multidrug Resistance Tuberculosis in the Context of Co-Infection in Ethiopia: A Systematic Review and Meta-Analysis.J Epidemiol Glob Health. 2025 Feb 5;15(1):19. doi: 10.1007/s44197-025-00360-7. J Epidemiol Glob Health. 2025. PMID: 39909956 Free PMC article.
References
-
- World Health Organization (WHO), Global tuberculosis report 2016 Geneva, Switzerland; WHO Press; 2016. Available from: http://www.who.int/tb/publications/global_report/en
-
- Anthony SF. Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: The National Institute of Allergy and Infectious Diseases Research Agenda and Recommendations for Priority Research. J of Inf Dis. 2008; 197:1493–1498. - PubMed
-
- Falzon D, Jaramillo E, Schünemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Geneva, Switzerland; WHO Press; 2011. - PubMed
-
- Parsons LM, Somoskövi Á, Gutierrez C, Lee E, Paramasivan CN, Abimiku AL,et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clinical microbiology reviews. 2011. April 1; 24(2): 314–350. doi: 10.1128/CMR.00059-10 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical